MİNİMAL İNVAZİV CERRAHİDE UTERİN MORSELASYON, UYGULANMALI MI ? UYGULANMAMALI MI ?
Son yıllarda jinekolojide minimal invaziv cerrahi, açık abdominal cerrahilere tercih edilmektedir. Minimal invaziv cerrahideki en büyük problemlerden biri büyük uterusların ve leiomyomların batın dışına çıkarılmasıdır. Bu amaçla morselatör olarak adlandırılan ve dokuların elektromekanik güç ile ya da manuel olarak küçük parçalara bölünerek batın dışına çıkarılmasını sağlayan cerrahi aletler kullanılmaktadır. The US Food and Drug Administration (FDA)’nın power morselatör kul-lanımı ile ilgili güvenlik uyarısı sonrasında, minimal invaziv cerrahide büyük uterus ve myomların çıkarılması ile ilgili derlemeler artmıştır. Tanı konulmamış uterin sarkomların morselasyonu neden-li, hastaların kötü sağkalım sonuçlarını gösteren bilimsel kanıtlar artmaktadır. Fakat şu anda okült uterus maligniteleri ile ilgili az sayıda veri bulunmaktadır. Biz bu derlemede, morselasyonun tanı konulmamış uterus malignitelerinin üzerindeki etkisini, uterin sarkomların preoperatif tanısı için kullanılabilecek radyolojik görüntüleme tekniklerini ve potansiyel malign dokuların intraabdomi-nal yayılımının nasıl önüne geçilebileceğini tartıştık fakat şu anki veriler ışığında klinik pratikte intraabdominal morselasyondan kaçınılmalıdır
UTERINE MORCELLATION IN MINIMALLY INVASIVE SURGERY, SHOULD BE APPLIED ? OR SHOULD NOT BE APPLIED ?
In recent years, minimally invasive surgery has been preferred to open abdominal procedures in gynecology. The one of the biggest problem in minimally invasive surgery is extraction of large uteri or myomas. For this purpose, morcellators are used for removal of tissues which are divided into small pieces with electromechanical or manuel power. Since the safety warning from the US Food and Drug Administration about the use of power morcellators, minimally invasive procedures involving the removal of large uterus and myomas are under review. Scientific proofs about that morcellation of undiagnosed uterine sarcomas is associated with worse survival outcomes of pa-tients are increasing. However currently a few data about morcellation of occult uterine malignan-cies are available. We will discuss the effects of morcellation of undiagnosed uterine malignancies, focusing on possible radiologic imaging techniques for preoperative diagnosis of uterine sarcoma and for avoiding intra-abdominal dissemination of potentially malignant tissues in this review. However, according to current data, intra-abdominal morcellation should be banned from clinical practice.
___
- 1. Schollmeyer T, Soyinka AS, Schollmeyer M, et al. Georg
Kelling (1866-1945): the root of modern day minimal invasive
surgery. A forgotten legend? Arch Gynecol Obstet
2007; 276:505–509.
- 2. Mouret G. From the first laparoscopic cholecystectomy to
the frontiers of laparoscopic surgery: the future prospectives.
Dig Surg 1991; 8:124–125
- 3. Schlaerth AC, Abu-Rustum NR. Role of minimally
invasive surgery in gynecologic cancers. Oncologist
2006;11:895-901.
- 4. Kho KA, Nezhat CH. Evaluating the risks of electric uterine
morcellation. JAMA 2014;311:905-906.
- 5. Larraín D, Rabischong B, Khoo CK, et al. “Iatrogenic”
parasitic myomas: Unusual late complication of laparoscopic
morcellation procedures. J Minim Invasive Gynecol
2010;17:719-724.
- 6. Hampton, T., 2014. Use of morcellation to remove fibroids
scrutinized at FDA hearings. JAMA 312, 588.
- 7. Larra´ın D, Rabischong B, Khoo CK et al. “Iatrogenic”
parasitic myomas: Unusual late complication of laparoscopic
morcellation procedures. J Minim Invasive Gynecol
2010;17:719–724.
- 8. Milad MP, Milad EA. Laparoscopic morcellatorrelated
complications. J Minim Invasive Gynecol 2014;21:486–
491.
- 9. Gerster AG. II.On the surgical dissemination of cancer.
Ann Surg 1885;2:98–109.
- 10. Dobronte Z, Wittman T, Karc´asony G. Rapid development
of malignant metastases in the abdominal wall aft er
laparocopy. Endoscopy 1978;10:127–130.
- 11. Bogani G, Cliby WA, Aletti GD. Impact of morcellation
on survival outcomes of patients with unexpected uterine
leiomyosarcoma: A systematic review andmeta-analysis.
Gynecol Oncol 2015;137: 167–172.
- 12. Hampton T. Critics of fibroid removal procedure question
risks it may pose for women with undetected uterine
cancer.JAMA 2014;311: 891–893.
- 13. Kho KA, Lin K, Hechanova M, Richardson DL. Risk of
Occult Uterine Sarcoma in Women Undergoing Hysterectomy
for Benign Indications. Obstet Gynecol. 2016
Mar;127(3):468-73.
- 14 Senapati S, Tu FF, Magrina JF.Power morcellators: a review
of current practice and assessment of risk.Am J Obstet
Gynecol. 2015 Jan;212(1):18-23.
- 15. Hagemann, I.S., Hagemann, A.R., LiVolsi, V.A., Montone,
K.T., Chu, C.S., 2011. Risk of occult malignancy in
morcellated hysterectomy: a case series. Int. J. Gynecol.
Pathol. 30 (5), 476–483.
- 16. Wright, J.D., Tergas, A.I., Burke, W.M., et al., 2014. Uterine
pathology in women undergoing minimally invasive
hysterectomy using morcellation. JAMA 312, 1253–1255.
17. Nagai, T., Takai, Y., Akahori, T., et al., 2014. Novel uterine
sarcoma preoperative diagnosis score predicts the need
for surgery in patients presenting with a uterine mass.
Springerplus 3, 678.
- 18. Skorstad M, Kent A, Lieng M. Uterine leiomyosarcoma
- incidence, treatment, and the impact of morcellation.
A nationwide cohort study. Acta Obstet Gynecol Scand.
2016 Sep;95(9):984-90.
- 19. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients
operated on for presumed leiomyoma and rapidly growing
leiomyoma. Obstet Gynecol 1994; 83:414–418.
20. Mahnert N, Morgan D, Campbell D et al. Unexpected
gynecologic malignancy diagnosed aft er hysterectomy
performed for benign indications. Obstet Gynecol
2015;125:397–405.
- 21. Giorgio B, Valentina C, Antonino D et al. Morcellation of
undiagnosed uterine sarcoma: A critical review. Critical
Reviews in Oncology/Hematology 98 (2016) 302–308
- 22. Van den Bosch, T., Dueholm, M., Leone, F.P., et al., 2015.
Terms and definitions for describing myometrial pathology
using ultrasonography. Ultrasound Obstet. Gynecol.
- 23. Nitta, E., Kanenishi, K., Itabashi, N., Tanaka, H., Hata, T.,
2014. Real-time tissue elastography of uterine sarcoma.
Arch. Gynecol. Obstet. 289, 463–465.
- 24. Namimoto T, Yamashita Y, Awai K et al. Combined use of
T2-weighted and diff usionweighted 3-T MR imaging for
diff erentiating uterine sarcomasfrombenignleiomyomas.
Eur Radiol 2009; 19:2756–2764.
- 25. J.R. Lorain, M.S. Piver, Uterine sarcomas: clinical features
and management, in: X. Coppleson, J. Monaghan, P. Morrow,
M. Tattersall (Eds.), Gynecologic Oncology, Churchill
Livingstone, London 1992, pp. 827–840.
- 26. Artioli, G., Wabersich, J., Ludwig, K., Gardiman, M.P.,
Borgato, L., Garbin, F., 2015. Rare uterine cancer: carcinosarcomas:
review from histology to treatment. Crit.
Rev. Oncol. Hematol. 94, 98–104.
- 27. Gadducci, A., 2011. Prognostic factors in uterine sarcoma.
Best Pract. Res. Clin. Obstet. Gynaecol. 25, 783–795.
- 28. Raspagliesi F, Maltese G, Bogani G, et all. Morcellation
worsens survival outcomes in patients with undiagnosed
uterine leiomyosarcomas: A retrospective MITO
group study. Gynecol Oncol. 2016 Nov 4. pii: S0090-
8258(16)31519-0.
- 29. Guo, X.M., Xu, X., Desai, V.B., 2015. Alterations in surgical
technique following FDA statement on power morcellation.
Am. J. Obstet. Gynecol.
- 30. Harris JA, Swenson CW, Uppal S, et al. Practice patterns
and postoperative complications before and aft er US
Food and Drug Administration safety communication
on power morcellation. Am J Obstet Gynecol. 2016
Jan;214(1):98.e1-98.e13.
- 31. Einstein MH, Barakat RR, Chi DS et al. Management of
uterine malignancy found incidentally aft er supracervical
hysterectomy or uterinemorcellation for presumed benign
disease. Int J Gynecol Cancer 2008;18:1065–1070.
- 32. Kho KA, Brown DN. Surgical Treatment of Uterine Fibroids
Within a Containment System and Without Power
Morcellation.Clin Obstet Gynecol. 2016 Mar;59(1):85-92.
- 33. Parker WH1, Pritts EA, Olive DL. What is the Future
of Open Intraperitoneal Power-Morcellation of
Fibroids?Clin Obstet Gynecol. 2016 Mar;59(1):73-84.
- 34. Nieboer TE, JohnsonN, LethabyAet al. Surgical approach
to hysterectomy for benign gynaecological disease. Cochrane
Database Syst Rev 2009; CD003677.
- 35. Serur E, Lakhi N. Laparoscopic hysterectomy with manual
morcellation of the uterus: An original technique that
permits the safe and quick removal of a large uterus. Am
J Obstet Gynecol 2011;204: 566.e1–566.e2.
- 36. Montella F, Riboni F, Cosma S et al. A safe method of
vaginal longitudinal morcellation of bulky uterus with
endometrial cancer in a bag at laparoscopy. Surg Endosc
2014;28:1949–1953.
- 37. Cohen SL, Einarsson JI, Wang KC et al. Contained power
morcellation within an insuffl ated isolation bag. Obstet
Gynecol 2014;124:491–497.
- 38. Moawad GN, Samuel D, Abi Khalil ED. Abdominal Approaches
to Tissue Containment and Extraction in Minimally
Invasive Gynecologic Surgery.J Minim Invasive
Gynecol. 2016 Nov - Dec;23(7):1032.
- 39. Cohen SL, Morris SN, Brown DN et al. Contained tissue
extraction using power morcellation: prospective evaluation
of leakage parameters.Am J Obstet Gynecol. 2016
Feb;214(2):257.e1-6
- 40. Steiner RA, Wight E, Tadir Y et al. Electrical cutting device
for laparoscopic removal of tissue from the abdominal
cavity. Obstet Gynecol 1993;81: 471–474.
- 41. 510(k) premarket notification. Device name: KSE Steiner
electromechanic morcellator. Available at http://www.
accessdata.fda.gov/scripts/cdrh/ cfdocs/cfPMN/pmn.
cfm?ID5K946147. Accessed January 29, 2015.
- 42. Seidman MA, Oduyebo T, Muto MG et al. Peritoneal
dissemination complicating morcellation of uterine mesenchymal
neoplasms. PLoS One 2012; 7:e50058.
- 43. GO position statement: Morcellation. Avail- able at
https://www.sgo.org/newsroom/position- statements-2/
morcellation/. Accessed January 29, 2015.
- 44. Updated: Laparoscopic uterine power morcel- lation in
hysterectomy and myomectomy: FDA safety communication.
Available at http://www. fda.gov/MedicalDevices/
Safety/AlertsandNotices/ ucm424443.htm. Accessed January
30, 2015.
- 45. ACOG statement: FDA issues safety communi- cation
on laparoscopic uterine power morcellation in hysterectomy
and myomectomy. Available at http:// www.acog.
org/About-ACOG/Announcements/FDA- Issues-Safety Communication-on-Laparoscopic-Uterine- Power-Morcellation.
Accessed January 30, 2015
- 46. AAGL statement to the FDA on power morcellation. Available
at http://www.aagl.org/ aaglnews/aagl-statementto-the-fda-on-power-
morcellation/. Accessed January
30, 2015.
- 47. Levitz J. FBI is investigating hysterectomy device found to
spread uterine cancer. Available at http://www.wsj.com/
articles/fb i-is-investigating- surgical-device-1432746641.
Accessed June 7, 2015.